Details for New Drug Application (NDA): 204516
✉ Email this page to a colleague
The generic ingredient in BRISDELLE is paroxetine mesylate. There are thirty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the paroxetine mesylate profile page.
Summary for 204516
Tradename: | BRISDELLE |
Applicant: | Sebela Ireland Ltd |
Ingredient: | paroxetine mesylate |
Patents: | 4 |
Suppliers and Packaging for NDA: 204516
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
BRISDELLE | paroxetine mesylate | CAPSULE;ORAL | 204516 | NDA AUTHORIZED GENERIC | Padagis US LLC | 0574-0279 | 0574-0279-30 | 30 CAPSULE in 1 BOTTLE (0574-0279-30) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 7.5MG BASE | ||||
Approval Date: | Jun 28, 2013 | TE: | AB | RLD: | Yes | ||||
Patent: | 7,598,271 | Patent Expiration: | May 4, 2025 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
Patent: | 8,658,663 | Patent Expiration: | Apr 6, 2029 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Patented Use: | TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE | ||||||||
Patent: | 8,946,251 | Patent Expiration: | Aug 4, 2026 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Patented Use: | TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE |
Expired US Patents for NDA 204516
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sebela Ireland Ltd | BRISDELLE | paroxetine mesylate | CAPSULE;ORAL | 204516-001 | Jun 28, 2013 | 5,874,447 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription